Jessica Leal-Porras, PA
Medical · McAllen, TXNPI 1588721666
Payments from drug & device makers
Across 330 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AstraZeneca$406
- AbbVie$389
- Amgen$385
- Dexcom, Inc.$278
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,98299%
- Education$260%
- Other$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 98 | $1,277 |
| Lilly USA, LLC | 64 | $1,191 |
| AstraZeneca | 17 | $406 |
| AbbVie | 30 | $389 |
| Amgen | 16 | $385 |
| Dexcom, Inc. | 10 | $278 |
| Boehringer Ingelheim | 8 | $259 |
| Johnson & Johnson | 8 | $246 |
| Sanofi-aventis U.S. LLC | 3 | $157 |
| Optinose US, Inc. | 8 | $132 |
| Corcept Therapeutics | 6 | $129 |
| Pfizer | 6 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $99 |
| Medtronic | 1 | $92 |
| Bayer | 4 | $86 |
| Phathom Pharmaceuticals, Inc. | 4 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| GSK | 4 | $64 |
| Exact Sciences | 3 | $54 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $48 |
| Sanofi Pasteur Inc. | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Nevro Corp. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Baxter Healthcare | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Acclarent, Inc | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$224
- SOLIQUA 100/33$125
- KISUNLA$125
- DEXCOM G6 TRANSMITTER$116
- ZEPBOUND$115
- MOUNJARO$115
- EVENITY$114
- XARELTO$114
How this compares
$6,038 in reported general payments places this provider in the 85th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 167 | $181,469 |
| JardianceEmpagliflozin | 63 | $94,204 |
| TradjentaLinagliptin | 43 | $55,623 |
| TrulicityDulaglutide | 39 | $54,945 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $52,600 |
| FarxigaDapagliflozin Propanediol | 32 | $40,393 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $32,794 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $32,049 |
| MyrbetriqMirabegron | 25 | $27,695 |
| JanuviaSitagliptin Phosphate | 21 | $26,970 |
| XareltoRivaroxaban | 15 | $26,420 |
| EliquisApixaban | 20 | $25,269 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $22,447 |
| RybelsusSemaglutide | 15 | $19,411 |
| MounjaroTirzepatide | 17 | $17,912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,277 | $200,880182 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $259 | $166,373127 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,191 | $72,85756 claims |
| AstraZenecaFarxiga | $406 | $40,39332 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $64 | $39,45952 claims |
| PfizerEliquis, Paxlovid | $111 | $28,11037 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $27,69525 claims |
| Johnson & JohnsonXarelto | $246 | $26,42015 claims |
| AbbVieLinzess, Synthroid | $389 | $13,99336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,490 medical providers in Texas.
Other medical in McAllen
- Jason HenslerMcAllen$66K
- Edgar GarciaMcAllen$17K
- Claudia MaldonadoMcAllen$15K
- Rolando VelazquezMcAllen$13K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.